Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss reduces hair thickness and coverage, but drug treatments mainly revive dormant hairs rather than reverse thinning; patients often undervalue their hair loss severity.

The role of antibodies in alopecia is unclear, but JAK inhibitors show promise for treatment.

COVID-19 may cause temporary hair loss due to direct damage to hair follicles, but it usually gets better on its own.

FMH foods may help manage post-acute COVID-19 symptoms safely and easily.

A COVID-19 patient had severe and long-lasting skin issues and unusual hair loss.

Monocytes might be linked to hair loss after COVID-19.

A patient experienced severe hair loss after getting an mRNA COVID-19 vaccine.

Standardized definitions and better methods are needed to accurately estimate long COVID-19 prevalence.

Maidenhair fern extract might help treat COVID-19 symptoms, but more research is needed.

A COVID-19 infected patient with chronic kidney disease experienced worsened kidney function, hair loss, and unexpected wart clearance.

A standardized drug development platform is essential for efficient and effective drug repurposing, especially during pandemics.

Many COVID-19 survivors continue to experience symptoms like fatigue and concentration problems after recovery, possibly needing rehabilitation.

COVID-19 can cause hair loss starting as early as 18 days after infection.

SIM01 significantly reduced post-COVID symptoms and is safe.

Long COVID causes lasting symptoms and needs ongoing care.

COVID-19 affects multiple body systems, not just the lungs.

Dermatologists should watch for skin symptoms in COVID-19 patients, prioritize urgent cases, and use telemedicine.

The study identified five types of long COVID symptoms and suggests tailored management strategies for each.

Women with PCOS may have a higher risk of severe COVID-19 due to hormonal imbalances and vitamin D deficiency.

Skin symptoms could help in early COVID-19 diagnosis but more research is needed to confirm their reliability.

Damaged skin has a weakened barrier, making it more vulnerable to substances and inflammation.

Pulmonary delivery of cepharanthine significantly improves its effectiveness and shows promise for treating lung fibrosis linked to COVID-19.

Canakinumab's effect on COVID-19 outcomes is unclear.

Most children with MIS-C showed significant improvement by 6 months.

70.7% of patients had long-COVID symptoms like fatigue, cough, and brain fog three months after recovery.

Long COVID symptoms are linked to immune issues, poor blood flow, and lung problems.

The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.

Ayurvedic Rasayan formulations like Chyawanprash may help manage post-COVID symptoms by boosting immunity.

Age, health conditions, race, and gender affect COVID-19 risk.

COVID-19 can cause skin changes, possibly from the virus, drugs, or lifestyle changes.